Mahfouz N M, Omar F A, Aboul-Fadl T
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, Assiut University, 71526, Assiut, Egypt.
Eur J Med Chem. 1999 Jul-Aug;34(7-8):551-62. doi: 10.1016/s0223-5234(00)80025-2.
Ester prodrugs of aspirin 1a, ibuprofen 1b, naproxen 1c and indomethacin 1d were synthesized using N-Hydroxymethylsuccinimide (HMSI) 3 and N-hydroxymethylisatin (HMIS) 4 as promoieties to reduce their gastrointestinal toxicity and improve bioavailability. Additionally, the kinetics of hydrolysis of the synthesized prodrugs 5a-d and 6a-d were studied at 37 degrees C in non-enzymatic simulated gastric fluid (SGF; hydrochloric acid buffer pH = 1.2); 0.02 M phosphate buffer (pH = 7.4); 80% human plasma and 10% rat liver homogenate. The results indicate higher chemical stability of the ester prodrugs in non-enzymatic SGF (t(1/2) congruent with 6.5-18.6 h) and rapid conversion to the parent drugs in 80% human plasma (t(1/2) congruent with 11.4-235 min) as well as in 10% rat liver homogenates (t(1/2) congruent with 12.0-90.0 min). As a general pattern, the HMSI esters 5a-d revealed higher chemical stability than the corresponding HMIS analogues 6a-d. The pH-rate profile of 5c and 6a indicated maximum stability of the former at pH = 1.2-8.0 and of the latter at pH = 1.2-4.0. The distribution coefficient (D(7.4)) values of the prodrugs 5a-d, 6a-d and the parent drugs 1a-d in an n-octanol/phosphate buffer (pH = 7.4) system indicated enhanced lipophilic properties of the prodrugs. Furthermore, the HMIS ester prodrugs 6a-d are more lipophilic than the corresponding HMSI derivatives 5a-d. In vivo ulcerogenicity studies using scanning electron microscopy on stomach specimens of rats treated with an oral dose for 4 d revealed that the synthesized ester prodrugs are significantly less irritating to gastric mucosa than the parent drugs. These results suggested HMSI and/or HMIS esters possess good potential as prodrugs with an improved therapeutic index for oral delivery of NSAIDs.
使用N-羟甲基琥珀酰亚胺(HMSI)3和N-羟甲基异吲哚酮(HMIS)4作为前体合成了阿司匹林1a、布洛芬1b、萘普生1c和吲哚美辛1d的酯前药,以降低它们的胃肠道毒性并提高生物利用度。此外,在37℃下,于非酶模拟胃液(SGF;盐酸缓冲液pH = 1.2)、0.02 M磷酸盐缓冲液(pH = 7.4)、80%人血浆和10%大鼠肝匀浆中研究了合成前药5a-d和6a-d的水解动力学。结果表明,酯前药在非酶SGF中具有更高的化学稳定性(t(1/2)约为6.5 - 18.6小时),并且在80%人血浆(t(1/2)约为11.4 - 235分钟)以及10%大鼠肝匀浆(t(1/2)约为12.0 - 90.0分钟)中能快速转化为母体药物。一般来说,HMSI酯5a-d比相应的HMIS类似物6a-d显示出更高的化学稳定性。5c和6a的pH-速率曲线表明,前者在pH = 1.2 - 8.0时具有最大稳定性,后者在pH = 1.2 - 4.0时具有最大稳定性。前药5a-d、6a-d以及母体药物1a-d在正辛醇/磷酸盐缓冲液(pH = 7.4)体系中的分配系数(D(7.4))值表明前药的亲脂性增强。此外,HMIS酯前药6a-d比相应的HMSI衍生物5a-d更具亲脂性。使用扫描电子显微镜对口服给药4天的大鼠胃标本进行的体内致溃疡研究表明,合成的酯前药对胃黏膜的刺激性明显小于母体药物。这些结果表明,HMSI和/或HMIS酯作为前药具有良好的潜力,可用于改善非甾体抗炎药口服给药的治疗指数。